Spyre Therapeutics (SYRE) AI Stock Analysis

• Market Cap: $736.34M
• Dividend Yield: N/A
• Average Volume (3M): 795.76K
• Price to Earnings (P/E): 2.3
• Beta (1Y): 1.13
• Revenue Growth: -100.00%
• EPS Growth: 94.68%
• Country: US
• Employees: 65
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -3.16
• Shares Outstanding: 60,257,023
• 10 Day Avg. Volume: 1,061,015
• 30 Day Avg. Volume: 795,763
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 1340.21
• Price to Cash Flow (P/CF): -7.40
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $54.67
• Price Target Upside: 347.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

Spyre Therapeutics' overall stock score reflects a challenging financial position with no revenue generation and consistent losses, which weigh heavily on its financial performance. The technical analysis indicates a bearish trend, and the valuation metrics highlight significant risks given the company's unprofitability and lack of dividends. These factors collectively suggest a cautious outlook for the stock.

Positive Factors

Development Strategy

The innovative multi-arm Phase 2 platform trial in ulcerative colitis is an ambitious development strategy that aims to rapidly evaluate programs and move towards combination development.

Product Potential

Lead program SPY001 demonstrated improved half-life compared to existing treatments, indicating potential for better efficacy.

Negative Factors

Clinical Data

SPY002 (TL1A) and SPY003 (IL-23) Ph1 topline data in UC and Ph2 initiations should barely move the stock.

Market Position

If for whatever reason the combo dream falls apart, Spyre would be left only with a late-to-market TL1A + convenience story, which would not be sufficient to justify stock valuation.

Spyre Therapeutics Business Overview & Revenue Model

Company Description

Spyre Therapeutics (SYRE) is a biotechnology company focused on developing innovative treatments for autoimmune diseases. Leveraging cutting-edge research and advanced therapeutic platforms, Spyre Therapeutics aims to address the unmet medical needs in this sector. The company's core products include novel biologics and small molecule drugs designed to modulate the immune system effectively, providing patients with improved outcomes and quality of life.

How the Company Makes Money

Spyre Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products. The company earns money by selling its approved drugs to healthcare providers, hospitals, and directly to patients through pharmacies. Additionally, Spyre may engage in strategic partnerships and collaborations with larger pharmaceutical companies for co-development, licensing, or distribution of its products, which can provide upfront payments, milestone payments, and royalties. The company's revenue model is also supported by research grants and funding for its clinical trials and development programs.

Spyre Therapeutics Financial Statement Overview

Summary

Spyre Therapeutics operates in the biotechnology industry with a high-risk financial profile characterized by consistent revenue challenges and profitability issues. While the balance sheet reflects a strong equity position, the lack of operational cash flow and persistent losses are concerning. The company needs significant revenue growth and profitability improvements to enhance its financial health.

Income Statement

Spyre Therapeutics has consistently struggled to generate revenue over the years, with recent data showing zero total revenue. The company has recorded negative EBIT and net income, leading to negative profit margins. Despite a slight improvement in EBIT, the overall lack of revenue and profitability presents significant challenges.

Balance Sheet

The balance sheet shows a strong equity position with no total debt reported in the latest period, resulting in a robust equity ratio. The company maintains a solid cash position, though the absence of revenue raises concerns about long-term sustainability. The return on equity remains negative due to ongoing net losses.

Cash Flow

Operating cash flow has been consistently negative, indicating challenges in generating cash from core operations. Despite positive financing activities that have bolstered cash reserves, the company struggles with negative free cash flow, which reflects ongoing operational inefficiencies.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	886.00K	2.33M	18.74M	0.00
	Gross Profit
0.00	-78.00K	365.00K	16.74M	-1.62M
	EBIT
-208.57M	-242.30M	-84.78M	-65.65M	-81.48M
	EBITDA
-208.57M	-127.82M	-83.21M	-63.66M	-79.27M
	Net Income Common Stockholders
-208.02M	-338.79M	-83.81M	-65.80M	-80.89M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
603.09M	339.28M	55.71M	93.13M	146.27M
	Total Assets
608.48M	341.86M	71.14M	109.93M	161.62M
	Total Debt
0.00	84.56M	4.63M	5.06M	5.45M
	Net Debt
-89.42M	-188.89M	-30.23M	-10.08M	-84.65M
	Total Liabilities
90.68M	157.84M	20.84M	25.98M	21.79M
	Stockholders Equity
517.80M	184.02M	50.30M	83.94M	139.83M
Cash Flow		Free Cash Flow
-157.41M	-99.91M	-80.18M	-54.29M	-80.06M
	Operating Cash Flow
-157.41M	-99.91M	-80.14M	-53.72M	-75.78M
	Investing Cash Flow
-353.29M	-108.39M	57.01M	-22.62M	-7.60M
	Financing Cash Flow
410.91M	361.08M	42.68M	1.39M	154.51M

Spyre Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRE, the sentiment is Negative. The current price of 12.22 is below the 20-day moving average (MA) of 15.82, below the 50-day MA of 18.90, and below the 200-day MA of 25.48, indicating a bearish trend. The MACD of -1.06 indicates Positive momentum. The RSI at 32.31 is Neutral, neither overbought nor oversold. The STOCH value of 15.26 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SYRE.

Spyre Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	51 Neutral	$758.40M	―	-38.09%	―	-13.90%	16.56%
RCUS	49 Neutral	$865.78M	―	-59.77%	―	120.51%	25.37%
Sector *	48 Neutral	$6.35B	1.19	-46.26%	2.67%	19.24%	1.75%
NRIX	48 Neutral	$696.79M	―	-64.16%	―	-30.25%	-5.92%
ZYME	45 Neutral	$662.19M	―	-30.54%	―	0.38%	6.94%
SYRE	38 Underperform	$736.34M	2.31	-42.90%	―	-100.00%	94.68%
PHVS	29 Underperform	$653.92M	―	-41.43%	―	―	0.71%

Spyre Therapeutics Corporate Events

Spyre Therapeutics Faces Internal Control Challenges

In a rapidly changing financial landscape, our company has identified a significant weakness in our internal control over financial reporting, particularly affecting earnings per share calculations. This issue could lead to material misstatements, impacting our financial condition and stock price. Management is committed to improving controls and believes that remediation efforts will enhance existing systems, but failure to rectify these issues promptly could undermine investor confidence and affect our Nasdaq listing.

Spyre Therapeutics Reports Promising Trial Results for SPY001

Spyre Therapeutics announced the promising interim results from its Phase 1 trial of SPY001, a novel monoclonal antibody targeting α4β7 for the treatment of inflammatory bowel disease. The trial revealed that SPY001, with a half-life exceeding 90 days, was well-tolerated and showed potential for long-term maintenance dosing, either every three or six months. Spyre plans to begin a Phase 2 trial in mid-2025, aiming to enhance the efficacy of current treatments with this innovative therapy and other combinations.